From the Editor

Aug 01, 2008
Pharmaceutical Executive
FDA preemption is a hot issue for pharma, and it's likely to get hotter. But it's the wrong issue.
Jul 01, 2008
Pharmaceutical Executive
It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with
Jun 01, 2008
Pharmaceutical Executive
The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?
Apr 01, 2008
Pharmaceutical Executive
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos
Apr 01, 2008
Pharmaceutical Executive
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos
Mar 01, 2008
Pharmaceutical Executive
For pharma to function, it needs a whole network that commands trust. The only alternative is the sort of regulation by mass tort that we've been sliding into in recent years
Feb 01, 2008
Pharmaceutical Executive
New from Pharm Exec: a blog, expanded tech and deals coverage, and a new awards program for emerging pharma leaders
Jan 01, 2008
Pharmaceutical Executive
A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?
Dec 01, 2007
Pharmaceutical Executive
For several decades, pharma got the message that promotion could make consumers want to use new drugs. The system didn't work with Pfizer's Exubera. That's surprising news, but is it bad news?
Nov 01, 2007
Pharmaceutical Executive
A hospital safety expert says it's now possible to completely eliminate certain adverse events. Pharma can't claim the same yet, but is it time for us to start imagining a time when we can "benchmark perfection"?
native1_300x100
lorem ipsum